| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5648093 | BAUSCH | Pharmaceutical and other dosage forms |
Jul, 2014
(9 years ago) | |
| US6423342 | BAUSCH | Process for the preparation of a solid pharmaceutical dosage form |
Mar, 2016
(8 years ago) | |
Zelapar is owned by Bausch.
Zelapar contains Selegiline Hydrochloride.
Zelapar has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Zelapar are:
- US5648093
- US6423342
Zelapar was authorised for market use on 14 June, 2006.
Zelapar is available in tablet, orally disintegrating;oral dosage forms.
The generics of Zelapar are possible to be released after 01 March, 2016.
Drugs and Companies using SELEGILINE HYDROCHLORIDE ingredient
Market Authorisation Date: 14 June, 2006
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
More Information on Dosage
ZELAPAR family patents
